As of September 12, 2026, a completed September mass-tort update is premature: the latest archived JPML report is from August, and the next hearing is September 24 in Chicago. The Judicial Panel on Multidistrict Litigation (JPML), which coordinates related federal cases before remand or trial, shows that major injury dockets remain active and largely unresolved. The most important changes involve settlement administration in Depo-Provera litigation, focused discovery in Paraquat cases, delayed AFFF/PFAS bellwether testing, and continued evidence gathering in GLP-1 and Suboxone litigation. Case totals show activity, not proof of injury, liability, eligibility, or recovery.
Table of Contents
- Why a September 2026 snapshot is not final
- What changed in Depo-Provera litigation?
- What should Paraquat claimants watch?
- Which other injury MDLs remain in pretrial development?
- What should a reader do with this update?
Why a September 2026 snapshot is not final
The JPML's newest archived pending-multidistrict-litigation report is dated August 3, 2026. Its next hearing is scheduled for September 24 in Chicago, so additional transfers, consolidations, or procedural developments may follow before the month ends. The JPML identifies the current status through its official August materials and hearing schedule: U.S.
Judicial Panel on Multidistrict Litigation. An mdl combines related federal cases for coordinated discovery and pretrial rulings. Individual plaintiffs generally keep their own claims, and cases may later settle, proceed to trial, or return to their original courts. The August figures show where activity is concentrated: These are docket counts labeled "actions pending." They do not establish that a product caused an injury or that any plaintiff qualifies for compensation, as the JPML's August report explains: Pending MDL Dockets by Actions Pending.
- Paraquat: 6,665 actions pending
- Depo-Provera: 6,294
- Paragard: 4,156
- GLP-1 general-products litigation: 3,928
- Bard-port litigation: 3,734
What changed in Depo-Provera litigation?
The Depo-Provera MDL court announced a July 22 settlement program for claims alleging meningiomas after use of Depo-Provera or covered generic products. The court said the program may resolve claims for a substantial percentage of plaintiffs, but defendants did not admit fault or liability. Registration closes November 30, 2026. A registration deadline is not the same as a guaranteed payment deadline or an eligibility finding.
Potential claimants must review the program's requirements and preserve records supporting product use, diagnosis, and medical treatment. The court stayed most MDL proceedings while the settlement program is implemented. Three pilot cases remain active, and a December 7 bellwether date depends on pending decisions involving preemption and Rule 702, the federal evidence rule governing expert testimony. These details appear in the court's August 10 order: Depo-Provera MDL Case Management Order 14.
What should Paraquat claimants watch?
The Paraquat litigation has moved toward targeted discovery for substantial settlement opt-outs. The court ordered selected opt-out cases to provide fact sheets, participate in depositions, and address specific proof of applicator licensing or Paraquat use. That matters because opting out of a settlement process does not end the evidentiary burden.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
A claimant may still need records showing exposure, product use, licensing or application history, diagnosis, and the medical theory connecting the exposure to the alleged injury. A public Paraquat status conference is set for September 15, 2026. The court's September materials and earlier June 3 update provide the current procedural markers: Southern District of Illinois Paraquat Products Liability Litigation.
Which other injury MDLs remain in pretrial development?
AFFF/PFAS litigation has experienced a later merits-testing milestone. The court postponed selection and expert-discovery proposals for Group B bellwether claims involving thyroid disease and ulcerative colitis from July 20 to November 20, 2026. The delay means those proposed cases will test the parties' evidence later than previously planned; it does not resolve the underlying claims. GLP-1 litigation remains divided between two tracks.
The August JPML report lists 3,928 actions in a general-products MDL, while a separate MDL involves 200 NAION vision-injury actions. The NAION court has entered detailed electronic-discovery rules, indicating that track remains in pretrial development rather than merits-resolved. The Suboxone-film MDL, with 1,827 actions pending in August, also remains focused on evidence gathering. The court requires authorized medical, dental, pharmacy, and treatment records within 30 days to document allegations involving dental erosion and decay. Record requests and deadlines can therefore become a practical priority for claimants.
What should a reader do with this update?
The procedural posture matters more than the headline case count. A person evaluating an injury claim should distinguish between a pending MDL, a settlement program, a bellwether case, and an individual claim that has actually been valued or resolved.
Useful checks include: For example, the Depo-Provera registration deadline and the Suboxone record-production requirement serve different purposes. One concerns entry into a settlement program; the other concerns proof developed during litigation.
- Identify the exact product, manufacturer, dates of use, and alleged injury.
- Preserve medical, pharmacy, dental, employment, and exposure records.
- Confirm whether the case is in an MDL, a settlement program, or separate litigation.
- Check every registration, fact-sheet, discovery, and document-production deadline.
- Treat a docket count as evidence of litigation volume, not evidence of entitlement to compensation.
You Might Also Like
- Arbitration Mass Tort Litigation September 2026 Update: What Changed, Why It Matters, and What to Watch Next
- Pharmaceutical Lawsuits Mass Tort Litigation August 2026 Update: What Changed, Why It Matters, and What to Watch Next
- Eligibility Tools Mass Tort Litigation August 2026 Update: What Changed, Why It Matters, and What to Watch Next